For Commercial Collaborator
Protheragen is professional in discovering and developing innovative antibody and CAR-T based immunotherapies for the treatment of various cancers. Currently, we have several promising pipelines in preclinical phase, including monoclonal antibody and CAR-T products. For commercial partners interested in our pipelines, Protheragen offers two solutions for you
1) licensing the antibody or CAR-T from our pipeline;
2) collaborating with us for the further development of the products in our pipeline to promote the progress to clinic and market , and the costs and future revenue are promised to be shared.
Protheragen also welcomes proposals from pharmaceutical and bio-tech companies interested in treating cancers by antibody and CAR-T based immunotherapies, and we have enriched experience and Ph.D level scientist team to help you boost your projects.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |